/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Hepion Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.17 -0.1879(-18.79%) HEPA at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 0.31
Highest Today 0.414
Today’s Open 0.385
Prev. Close 0.3916
52 Week High 68.00
52 Week Low 0.25
Day’s Range: Low 0.31 High 0.414
52-Week Range: Low 0.25 High 68.00
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -35.55
3 year return -95.88
5 year return -99.01
10 year return -

Institutional Holdings

Anson Funds Management LP 0.43

BlackRock Inc 0.15

Vanguard Group Inc 0.09

Geode Capital Management, LLC 0.08

Susquehanna International Group, LLP 0.05

Renaissance Technologies Corp 0.03

State Street Corp 0.03

Fidelity Extended Market Index 0.03

UBS Group AG 0.03

PNC Financial Services Group Inc 0.01

Tower Research Capital LLC 0.01

Vanguard Institutional Extnd Mkt Idx Tr 0.01

Morgan Stanley - Brokerage Accounts 0.00

Extended Equity Market Fund K 0.00

Fidelity Series Total Market Index 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Extended Equity Market Fund M 0.00

Federation des caisses Desjardins du Quebec 0.00

Spartan Total Market Index Pool E 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Advisor Group Holdings, Inc. 0.00

Group One Trading, LP 0.00

SBI Securities Co Ltd 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

Bank of America Corp 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

NT Ext Eq Mkt Indx Fd DC Lend T4 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

Barclays PLC 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

BNYM Mellon SL Market Completion UC1 0.00

Hanson Mcclain Inc 0.00

Northern Trust Investments N A 0.00

SignatureFD, LLC 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4.30 M

PB Ratio 2.1125

PE Ratio 0.0

Enterprise Value 8.47 M

Total Assets 1.61 M

Volume 4368896

Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:-67131 -0.1M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-48926042 -48.9M, FY23:-44677888 -44.7M, FY22:-42200049 -42.2M, FY21:-32731027 -32.7M, FY20:-20353938 -20.4M

Quarterly Revenue Q1/2025:null 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:109730 0.1M, Q4/2023:0 0.0M

Quarterly Profit Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M, Q1/2024:-30758 -0.0M, Q4/2023:null 0.0M

Quarterly Net worth Q1/2025:-1547454 -1.5M, Q3/2024:-4865948 -4.9M, Q2/2024:-3925212 -3.9M, Q1/2024:-2853806 -2.9M, Q4/2023:-11059628 -11.1M

Fund house & investment objective

Company Information Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow